* Helius Medical Technologies Inc HSDT.OQ reported a
quarterly
adjusted loss of $3.08 per share for the quarter ended in
March, higher than the same quarter last year, when the company
reported EPS of $-4.50. The mean expectation of three analysts
for the quarter was for a loss of $3.87 per share. Wall Street
expected results to range from $-5.04 to $-2.70 per share.
* Revenue rose 21.6% to $135.00 thousand from a year ago;
analysts
expected $130.50 thousand.
* Helius Medical Technologies Inc's reported EPS for the
quarter
was a loss of $3.08.
* The company reported a quarterly loss of $2.52 million.
* Helius Medical Technologies Inc shares had fallen by 72.0%
this
quarter and lost 79.7% so far this year.
FORECAST CHANGES
* The mean earnings estimate of analysts had fallen by
about 14.7%
in the last three months.
* In the last 30 days, there have been no earnings estimate
revisions by analysts covering the company.
RECOMMENDATIONS
* The current average analyst rating on the shares is "buy"
and
the breakdown of recommendations is 3 "strong buy" or "buy," no
"hold" and no "sell" or "strong sell."
* The average consensus recommendation for the advanced
medical
equipment & technology peer group is also "buy"
Wall Street's median 12-month price target for Helius Medical
Technologies Inc is $15.00
This summary was machine generated from LSEG data May 13 at
09:38 p.m. UTC. All figures in US dollars unless otherwise
stated. (For questions concerning the data in this report,
contact Estimates.Support@lseg.com. For any other questions or
feedback, contact RefinitivNewsSupport@thomsonreuters.com) QUARTER ENDING ESTIMATE ACTUAL BEAT, MET,
MISSED
Mar. 31 2024 -3.87 -3.08 Beat
Dec. 31 2023 -3.77 -1.47 Beat
Sep. 30 2023 -6.00 -5.49 Beat
Jun. 30 2023 -5.83 -3.00 Beat